Stock DSNKY DAIICHI SANKYO COMPANY, LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Daiichi Sankyo Company, Limited OTC Markets

Equities

DSNKY

US23381D1028

Market Closed - OTC Markets
Other stock markets
 20:59:13 31/05/2024 BST 		5-day change 1st Jan Change
35.38 USD +2.61% Intraday chart for Daiichi Sankyo Company, Limited +2.17% +29.36%
05-28 RevolKa Signs Master Service Agreement with Daiichi Sankyo CI
05-27 AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Daiichi Sankyo - Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
AQ
RevolKa Signed Master Service Agreement with Daiichi Sankyo
AQ
RevolKa Signs Master Service Agreement with Daiichi Sankyo
CI
AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients
DJ
AstraZeneca, Daiichi Sankyo’s Lung Cancer Drug Shows Mixed Results in Late-stage Trial
MT
AstraZeneca's Lung Cancer Drug Shows Clinically Meaningful Improvement in Overall Survival
MT
Astra, Daiichi hail positive survival data for Dato-DXd
AN
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
BU
Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial
CI
Jefferies Adjusts Daiichi Sankyo’s Price Target to 6,600 Yen From 5,600 Yen, Keeps at Buy
MT
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
BU
AstraZeneca to build $1.5-bln cancer drug plant in Singapore
RE
Merck to present new oncology data
CF
IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court
MT
Daiichi Sankyo : Announces Appointments of Directors(251.4KB
PU
Japan's Nikkei closes at 3-week high on US rate-cut outlook, tech boost
RE
Japan's Nikkei climbs on Fed rate-cut outlook, tech boost
RE
Remsons, Daiichi Infotainments Form Joint Venture
MT
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement
MT
AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. DSNKY Stock
  5. News Daiichi Sankyo Company, Limited